Sami M Ali, MD
Hematology/Oncology · Snellville
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
- Since medical school
- 15 years
- Graduated 2011
Offices
3 locations · Piedmont Providers LLC · The Oncology Institute CA, A Professional Corporation
Looking this up.
Hospitals listed: California Hospital Medical Center La. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ali’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A149539 · Current
Licensed to practise in California · since 2017 · expires 2027-01-31 · American University of the Caribbean School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Hematology
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Hospital Medical Center LaLos Angeles, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 2 of 5 · 64% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.344, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.162, Oct 2024 – Sep 2025
See every measure and the patient survey for California Hospital Medical Center La
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 2 better, 4 the same, 2 worse of 8 measures. Readmissions: 0 better, 5 the same, 1 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.344 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.162 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 292 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.63 to 1.48) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10.2 · 71 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.2 · 110 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 940 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 1,577 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,597 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (0.64 to 5.65) · 248 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.67 (0 to 3.4) · 33 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.16 (0.49 to 3.83) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.82 (0 to 18.7) · 40 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.17 (0.86 to 9.49) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 44 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.98 (0.07 to 1.89) · 1,439 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 100 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.872 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.512 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 2.188 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 54 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 249 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 88.4 · 88 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -2.3 · 44 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 121 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 112 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.9 · 57 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.7) · 62 cases | No different | Jan 2022 – Dec 2024 |
What patients said (561 patients answered, 7% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 69% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 80% |
| Yes, staff "did" give patients information about help after discharge | 79% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 66% |
| Doctors "always" treated them with courtesy and respect | 77% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 81% |
Original Medicare doctor bills
$546,773
Medicare paid this office $546,773 for 173 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 82 | $19,545 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $10,579 | $143 |
| Administration of chemotherapy into vein, 1 hour or less | 19 | $9,894 | $121 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 16 | $7,771 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $6,622 | $66 |
See all 12 services
| Return visit (30+ min) | 82 | $19,545 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $10,579 | $143 |
| Administration of chemotherapy into vein, 1 hour or less | 19 | $9,894 | $121 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 16 | $7,771 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $6,622 | $66 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 17 | $1,990 | $26 |
| Short return visit (20+ min) | 27 | $1,783 | $59 |
| New patient visit (45+ min) | 12 | $1,316 | $110 |
| Insertion of needle into vein for collection of blood sample | 25 | $381 | $9 |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $57 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 12 | $46 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 13 | $43 | None |
Who their Medicare patients are
173 Original Medicare patients in 2024. Average age 70 · Under 65 17% · 85 and older 7% · Women 57% · Also on Medicaid 94% · Health risk score 2.42. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Diabetes 53% · Cancer 47% · Chronic kidney disease 38% · Coronary heart disease 37% · Depression 29% · COPD 27% · Heart failure 25% · Atrial fibrillation 23% · Dementia 17% · Stroke 17%.
The office billed $1,529,982, Medicare allowed $690,657 and paid $546,773; for 23,252 services of 73 kinds; $478,077 of it was for drugs given in the office and $68,696 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 173 | 23,252 | 70 | 2.42 | $1,529,982 | $546,773 |
| 2023 | 219 | 20,316 | 70 | 1.98 | $1,113,625 | $433,202 |
| 2022 | 172 | 32,438 | 69 | 2.46 | $1,685,339 | $656,708 |
| 2021 | 173 | 8,066 | 70 | 2.55 | $641,542 | $259,496 |
| 2020 | 140 | 13,716 | 69 | 3.28 | $465,771 | $173,206 |
| 2019 | 106 | 6,689 | 71 | 2.29 | $218,403 | $87,289 |
| 2018 | 87 | 1,000 | 72 | 2.57 | $63,828 | $35,089 |
| 2017 | 236 | 1,151 | 73 | 3.10 | $250,926 | $54,331 |
| 2016 | 228 | 555 | 70 | 3.04 | $133,417 | $51,128 |
| 2015 | 164 | 277 | 70 | 2.61 | $56,512 | $24,132 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 93 | $24,581 | $100 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 71 | $10,504 | $140 |
| Administration of chemotherapy into vein, 1 hour or less | 14 | $9,479 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 56 | $9,310 | $67 |
| New patient visit (45+ min) | 21 | $2,718 | $129 |
| Short return visit (20+ min) | 18 | $1,280 | $71 |
| Short return visit (20+ min) | 13 | $1,018 | $68 |
| Insertion of needle into vein for collection of blood sample | 35 | $518 | $8 |
| Assessment of emotional or behavioral problems | 23 | $88 | $4 |
2022: 12 services
| Return visit (30+ min) | 77 | $22,025 | $102 |
| Administration of chemotherapy into vein, 1 hour or less | 22 | $18,095 | $130 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $15,005 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 61 | $11,150 | $61 |
| Administration of chemotherapy into vein, each additional hour | 13 | $2,954 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 18 | $2,686 | $28 |
| Administration of additional new drug or substance into vein, 1 hour or less | 11 | $2,596 | $63 |
| New patient visit (45+ min) | 11 | $1,490 | $135 |
| Injection, dexamethasone sodium phosphate, 1 mg | 16 | $133 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 15 | $92 | None |
| Insertion of needle into vein for collection of blood sample | 17 | $71 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 13 | $55 | None |
2021: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 81 | $18,564 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 88 | $16,618 | $171 |
| Return visit (30+ min) | 58 | $15,127 | $106 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 13 | $9,280 | $160 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | $3,060 | $96 |
2020: 7 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 73 | $14,331 | $173 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 68 | $12,851 | $63 |
| Return visit (30+ min) | 43 | $8,347 | $83 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 14 | $7,174 | $159 |
| Telephone medical discussion with physician, 21-30 minutes | 26 | $3,808 | $89 |
| Long return visit (40+ min) | 22 | $3,056 | $113 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 11 | $61 | None |
2019: 5 services
| Return visit (30+ min) | 46 | $11,903 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $8,943 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $4,862 | $61 |
| New patient visit (60+ min) | 14 | $1,984 | $142 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 13 | $37 | None |
2018: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $6,717 | $164 |
| Return visit (30+ min) | 29 | $4,500 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,765 | $59 |
| New patient visit (60+ min) | 11 | $1,867 | $170 |
2017: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 159 | $21,738 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $9,314 | $179 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $5,949 | $92 |
| Hospital discharge day management, more than 30 minutes | 33 | $3,228 | $95 |
2016: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 130 | $17,214 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 86 | $16,152 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 75 | $14,113 | $181 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,401 | $93 |
2015: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 88 | $10,081 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,082 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $3,944 | $88 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,763 | $126 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,307 | $93 |
Medicaid work
$51,370 in 2024
Medicaid paid $51,370 for 4,100 billed services this clinician did in 2024, up to 122 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 1,062 | $11,526 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 318 | $10,971 |
| 1ST HOSP IP/OBS HIGH 75 | 191 | $4,717 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 302 | $4,665 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 381 | $4,277 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 447 | $3,545 |
| New patient visit (45+ min) | 160 | $3,513 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 357 | $2,596 |
| IP/OBS CONSLTJ NEW/EST PT HIGH MDM 80 MINUTES | 93 | $2,292 |
| Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) | 119 | $1,526 |
| Short return visit (20+ min) | 113 | $576 |
| Injection, diphenhydramine hcl, up to 50 mg | 247 | $331 |
| 2024 | 4,100 | 16 | 122 | $51,370 |
| 2023 | 6,175 | 20 | 205 | $100,641 |
| 2022 | 4,336 | 15 | 149 | $119,303 |
| 2021 | 3,182 | 15 | 87 | $77,912 |
| 2020 | 2,258 | 10 | 102 | $59,233 |
| 2019 | 1,494 | 8 | 80 | $52,114 |
| 2018 | 681 | 6 | 77 | $6,502 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 1,973 | $31,055 |
| 1ST HOSP IP/OBS HIGH 75 | 373 | $16,795 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 880 | $16,697 |
| New patient visit (45+ min) | 345 | $8,576 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 227 | $7,832 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 355 | $6,887 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 273 | $4,574 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 417 | $2,619 |
| Iron sucrose injection | 133 | $1,665 |
| Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) | 90 | $810 |
| Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) | 96 | $743 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 253 | $680 |
2022
| Return visit (30+ min) | 1,426 | $38,123 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 322 | $22,490 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 974 | $18,788 |
| 1ST HOSP IP/OBS HIGH 75 | 322 | $12,753 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 305 | $12,391 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 268 | $9,246 |
| New patient visit (45+ min) | 263 | $3,561 |
| Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) | 33 | $512 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 26 | $455 |
| Long return visit (40+ min) | 27 | $446 |
| Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) | 34 | $229 |
| Injection, dexamethasone sodium phosphate, 1 mg | 154 | $133 |
2021
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 902 | $19,426 |
| Return visit (30+ min) | 812 | $15,797 |
| 1ST HOSP IP/OBS HIGH 75 | 306 | $14,650 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 183 | $11,192 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 246 | $8,487 |
| Short return visit (20+ min) | 293 | $3,058 |
| New patient visit (60+ min) | 54 | $2,265 |
| New patient visit (45+ min) | 106 | $1,360 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 164 | $1,180 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 15 | $149 |
| Injection, diphenhydramine hcl, up to 50 mg | 19 | $142 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 14 | $112 |
2020
| Return visit (30+ min) | 890 | $18,938 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 608 | $16,509 |
| 1ST HOSP IP/OBS HIGH 75 | 199 | $10,090 |
| New patient visit (60+ min) | 166 | $5,911 |
| Long return visit (40+ min) | 117 | $3,267 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 59 | $2,036 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 36 | $1,035 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 131 | $959 |
| Short return visit (20+ min) | 34 | $264 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 18 | $225 |
2019
| Return visit (30+ min) | 875 | $37,524 |
| 1ST HOSP IP/OBS HIGH 75 | 143 | $6,281 |
| New patient visit (60+ min) | 106 | $3,070 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 44 | $2,513 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 175 | $2,291 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 35 | $242 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 81 | $143 |
| Injection, dexamethasone sodium phosphate, 1 mg | 35 | $50 |
2018
| Return visit (30+ min) | 508 | $4,528 |
| 1ST HOSP IP/OBS HIGH 75 | 14 | $939 |
| New patient visit (60+ min) | 74 | $579 |
| Long return visit (40+ min) | 30 | $238 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 20 | $201 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 35 | $19 |
Drugs they prescribed that Part D paid
$3,791,685
Pharmacies billed $3,791,685 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 8% of their Part D prescriptions (85 of 1,042) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 13% of their opioid prescriptions.
685 generic and 357 brand-name prescriptions · $3,791,685 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lenvima | 20 | $456,707 | $22,835 |
| Xtandi | 31 | $401,548 | $12,953 |
| Keytruda | 31 | $345,490 | $11,145 |
| Lenalidomide | 18 | $191,586 | $10,644 |
| Venclexta | 11 | $141,568 | $12,870 |
See all 30 drugs
| Lenvima | 20 | $456,707 | $22,835 |
| Xtandi | 31 | $401,548 | $12,953 |
| Keytruda | 31 | $345,490 | $11,145 |
| Lenalidomide | 18 | $191,586 | $10,644 |
| Venclexta | 11 | $141,568 | $12,870 |
| Libtayo | 12 | $113,169 | $9,431 |
| Xgeva | 31 | $95,742 | $3,088 |
| Ruxience | 14 | $77,629 | $5,545 |
| Lupron Depot | 11 | $61,352 | $5,577 |
| Truxima | 11 | $55,288 | $5,026 |
| Abiraterone Acetate | 29 | $31,585 | $1,089 |
| Eligard | 14 | $16,892 | $1,207 |
| Eliquis | 24 | $16,390 | $683 |
| Pemetrexed Disodium | 23 | $8,251 | $359 |
| Anastrozole | 90 | $1,558 | $17 |
| Zoledronic Acid | 21 | $1,013 | $48 |
| Letrozole | 48 | $846 | $18 |
| Ondansetron Odt | 51 | $767 | $15 |
| Hydrocodone-Acetaminophen | 28 | $731 | $26 |
| Acetaminophen-Codeine | 20 | $522 | $26 |
| Oxycodone-Acetaminophen | 18 | $516 | $29 |
| Triamcinolone Acetonide | 11 | $412 | $37 |
| Dexamethasone | 23 | $375 | $16 |
| Hydroxyurea | 23 | $308 | $13 |
| Loperamide | 15 | $93 | $6 |
| Prednisone | 27 | $92 | $3 |
| Folic Acid | 14 | $51 | $4 |
| Ondansetron | 13 | $29 | $2 |
| Diphenhydramine | 14 | $26 | $2 |
| Dexamethasone Sodium Phosphate | 11 | $19 | $2 |
Year by year
| 2024 | 1,042 | 186 | 8% (85) | 34% | $3,791,685 |
| 2023 | 882 | 184 | 6% (53) | 34% | $3,482,733 |
| 2022 | 944 | 189 | 8% (72) | None | $3,474,392 |
| 2021 | 944 | 158 | 10% (92) | 38% | $3,755,188 |
| 2020 | 978 | 189 | 6% (62) | 39% | $3,477,788 |
| 2019 | 925 | 183 | 8% (69) | 36% | $2,876,364 |
| 2018 | 517 | 132 | 5% (28) | 30% | $1,462,139 |
| 2017 | 121 | 46 | None | 23% | $178,083 |
| 2016 | 55 | 17 | None | None | $42,804 |
| 2015 | 15 | None | 0% (0) | None | $35,277 |
| 2014 | 127 | 22 | None | None | $10,185 |
| 2013 | 165 | 30 | None | None | $11,075 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Keytruda | 53 | $625,648 | $11,805 |
| Xtandi | 24 | $321,869 | $13,411 |
| Lenvima | 12 | $297,365 | $24,780 |
| Tagrisso | 17 | $293,178 | $17,246 |
| Imbruvica | 13 | $206,350 | $15,873 |
| Venclexta | 15 | $203,461 | $13,564 |
| Gilotrif | 14 | $162,322 | $11,594 |
| Xgeva | 24 | $72,209 | $3,009 |
| Abiraterone Acetate | 11 | $52,923 | $4,811 |
| Eliquis | 13 | $11,777 | $906 |
| Pemetrexed Disodium | 25 | $6,692 | $268 |
| Anastrozole | 79 | $3,139 | $40 |
| Zoledronic Acid | 21 | $1,759 | $84 |
| Ondansetron Odt | 74 | $1,309 | $18 |
| Hydrocodone-Acetaminophen | 26 | $1,025 | $39 |
| Dexamethasone | 26 | $392 | $15 |
| Acetaminophen-Codeine | 17 | $375 | $22 |
| Hydroxyurea | 16 | $338 | $21 |
| Letrozole | 17 | $298 | $18 |
| Fluticasone Propionate | 11 | $242 | $22 |
| Prednisone | 18 | $106 | $6 |
| Sertraline | 13 | $99 | $8 |
| Folic Acid | 19 | $31 | $2 |
2022: 22 drugs
| Imbruvica | 42 | $640,726 | $15,255 |
| Keytruda | 27 | $304,045 | $11,261 |
| Xtandi | 22 | $300,459 | $13,657 |
| Tagrisso | 18 | $296,893 | $16,494 |
| Abiraterone Acetate | 60 | $294,592 | $4,910 |
| Tabrecta | 13 | $282,067 | $21,697 |
| Ninlaro | 16 | $185,096 | $11,568 |
| Lupron Depot | 11 | $59,089 | $5,372 |
| Eligard | 21 | $28,906 | $1,376 |
| Eliquis | 27 | $18,341 | $679 |
| Xarelto | 12 | $9,608 | $801 |
| Anastrozole | 123 | $2,885 | $23 |
| Ondansetron Odt | 69 | $1,766 | $26 |
| Hydroxyurea | 25 | $1,144 | $46 |
| Zoledronic Acid | 14 | $826 | $59 |
| Dexamethasone | 23 | $790 | $34 |
| Hydrocodone-Acetaminophen | 30 | $764 | $25 |
| Bicalutamide | 31 | $611 | $20 |
| Letrozole | 11 | $611 | $56 |
| Prednisone | 55 | $400 | $7 |
| Acetaminophen-Codeine | 15 | $391 | $26 |
| Furosemide | 11 | $35 | $3 |
2021: 26 drugs
| Imbruvica | 53 | $751,387 | $14,177 |
| Tagrisso | 31 | $482,525 | $15,565 |
| Xtandi | 26 | $332,452 | $12,787 |
| Retevmo | 16 | $331,660 | $20,729 |
| Tabrecta | 13 | $259,977 | $19,998 |
| Revlimid | 17 | $252,974 | $14,881 |
| Abiraterone Acetate | 38 | $161,810 | $4,258 |
| Ninlaro | 14 | $148,910 | $10,636 |
| Ogivri | 13 | $54,873 | $4,221 |
| Eliquis | 34 | $20,930 | $616 |
| Eligard | 15 | $20,454 | $1,364 |
| Xarelto | 12 | $8,307 | $692 |
| Anastrozole | 118 | $3,778 | $32 |
| Zoledronic Acid | 14 | $1,973 | $141 |
| Hydroxyurea | 54 | $1,594 | $30 |
| Dexamethasone | 31 | $957 | $31 |
| Bicalutamide | 33 | $955 | $29 |
| Ondansetron Odt | 41 | $755 | $18 |
| Tamoxifen Citrate | 13 | $640 | $49 |
| Hydrocodone-Acetaminophen | 44 | $610 | $14 |
| Morphine Sulfate Er | 19 | $556 | $29 |
| Letrozole | 12 | $347 | $29 |
| Tamsulosin | 17 | $206 | $12 |
| Prednisone | 32 | $192 | $6 |
| Hydromorphone | 12 | $189 | $16 |
| Furosemide | 11 | $34 | $3 |
2020: 23 drugs
| Imbruvica | 52 | $692,928 | $13,326 |
| Tagrisso | 43 | $658,543 | $15,315 |
| Revlimid | 33 | $425,177 | $12,884 |
| Afinitor | 18 | $284,167 | $15,787 |
| Xtandi | 19 | $223,065 | $11,740 |
| Abiraterone Acetate | 30 | $144,403 | $4,813 |
| Ninlaro | 13 | $134,230 | $10,325 |
| Herceptin | 19 | $96,877 | $5,099 |
| Procrit | 16 | $28,076 | $1,755 |
| Eliquis | 31 | $18,396 | $593 |
| Xarelto | 14 | $7,758 | $554 |
| Exemestane | 24 | $5,949 | $248 |
| Anastrozole | 117 | $3,860 | $33 |
| Hydroxyurea | 47 | $1,968 | $42 |
| Ondansetron Odt | 43 | $1,306 | $30 |
| Dexamethasone | 28 | $746 | $27 |
| Letrozole | 19 | $573 | $30 |
| Hydrocodone-Acetaminophen | 26 | $557 | $21 |
| Bicalutamide | 15 | $522 | $35 |
| Ondansetron | 11 | $418 | $38 |
| Tamoxifen Citrate | 11 | $322 | $29 |
| Oxycodone | 14 | $273 | $19 |
| Prednisone | 38 | $217 | $6 |
2019: 23 drugs
| Imbruvica | 66 | $810,228 | $12,276 |
| Revlimid | 38 | $564,809 | $14,863 |
| Tagrisso | 21 | $319,083 | $15,194 |
| Ibrance | 26 | $305,743 | $11,759 |
| Afinitor | 11 | $178,179 | $16,198 |
| Herceptin | 20 | $107,150 | $5,357 |
| Procrit | 15 | $36,260 | $2,417 |
| Eliquis | 31 | $17,309 | $558 |
| Anastrozole | 177 | $5,249 | $30 |
| Exemestane | 40 | $4,640 | $116 |
| Hydroxyurea | 61 | $2,345 | $38 |
| Anagrelide | 17 | $2,245 | $132 |
| Esomeprazole Magnesium | 11 | $754 | $69 |
| Letrozole | 31 | $737 | $24 |
| Ondansetron Odt | 18 | $685 | $38 |
| Morphine Sulfate Er | 11 | $304 | $28 |
| Oxycodone | 13 | $296 | $23 |
| Bicalutamide | 11 | $284 | $26 |
| Hydrocodone-Acetaminophen | 17 | $270 | $16 |
| Oxycodone-Acetaminophen | 14 | $189 | $13 |
| Pantoprazole | 18 | $122 | $7 |
| Ondansetron | 11 | $118 | $11 |
| Amlodipine Besylate | 12 | $74 | $6 |
2018: 10 drugs
| Revlimid | 28 | $412,571 | $14,735 |
| Imbruvica | 33 | $383,665 | $11,626 |
| Xtandi | 11 | $85,340 | $7,758 |
| Anastrozole | 103 | $4,888 | $47 |
| Exemestane | 13 | $3,570 | $275 |
| Hydroxyurea | 45 | $1,509 | $34 |
| Letrozole | 14 | $622 | $44 |
| Ondansetron Odt | 22 | $584 | $27 |
| Dexamethasone | 22 | $225 | $10 |
| Oxycodone-Acetaminophen | 11 | $177 | $16 |
2017: 1 drug
| Anastrozole | 18 | $322 | $18 |
2016: 1 drug
| Anastrozole | 18 | $143 | $8 |
2013: 2 drugs
| Amlodipine Besylate | 11 | $104 | $9 |
| Simvastatin | 12 | $88 | $7 |
Money from drug and device companies
$4,647 in 2025
| 2025 | 43 | 165 | None | $4,647 |
| 2024 | 43 | 257 | None | $6,496 |
| 2023 | 51 | 278 | $656 | $7,081 |
| 2022 | 46 | 264 | None | $5,248 |
| 2021 | 41 | 228 | None | $5,088 |
| 2020 | 38 | 122 | None | $2,665 |
| 2019 | 38 | 137 | None | $2,626 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Kisqali | $1,261 | 24 payments
|
| Janssen Biotech | Tecvayli | $337 | 13 payments
|
| Daiichi Sankyo | Enhertu | $255 | 12 payments
|
| Gilead Sciences | Trodelvy | $203 | 8 payments
|
| Pfizer | Ibrance | $203 | 10 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $184 | 8 payments
|
See all 164 published payments
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-12-30 | Kisqali | $83 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-11-26 | Kisqali | $83 |
| ARS Pharmaceuticals Operations | Meals · 2025-11-13 | Neffy | $29 |
| Legend Biotech USA | Meals · 2025-11-10 | Carvykti | $22 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-10-23 | Kisqali | $83 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-23 | Imfinzi | $26 |
| Incyte | Meals · 2025-10-21 | Jakafi | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-20 | None | $22 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-20 | None | $21 |
| Janssen Biotech | Meals · 2025-10-16 | Erleada | $23 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-16 | Nubeqa | $23 |
| Gilead Sciences | Meals · 2025-10-15 | Trodelvy | $25 |
| Janssen Biotech | Meals · 2025-10-10 | Tecvayli | $22 |
| Array Biopharma | Meals · 2025-10-09 | Braftovi | $19 |
| Genzyme | Meals · 2025-10-08 | Wayrilz | $26 |
| Jazz Pharmaceuticals | Meals · 2025-10-08 | None | $22 |
| Gilead Sciences | Meals · 2025-10-07 | Trodelvy | $17 |
| GlaxoSmithKline | Meals · 2025-10-03 | Jemperli | $19 |
| Janssen Biotech | Meals · 2025-10-02 | Rybrevant | $21 |
| Daiichi Sankyo | Meals · 2025-10-02 | Datroway | $20 |
| Daiichi Sankyo | Meals · 2025-10-02 | Datroway | $1 |
| Progenics Pharmaceuticals | Meals · 2025-10-01 | Pylarify | $16 |
| Astellas Pharma US | Meals · 2025-09-30 | Vyloy | $27 |
| Pfizer | Meals · 2025-09-29 | Padcev | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-23 | Opdualag | $28 |
| Daiichi Sankyo | Meals · 2025-09-23 | Enhertu | $24 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-09-19 | Kisqali | $83 |
| Abbvie | Meals · 2025-09-18 | Epkinly | $13 |
| Regeneron Healthcare Solutions | Meals · 2025-09-16 | Lynozyfic | $24 |
| Regeneron Healthcare Solutions | Meals · 2025-09-15 | Libtayo | $27 |
| EMD Serono | Meals · 2025-09-10 | None | $27 |
| Abbvie | Meals · 2025-09-09 | Elahere | $19 |
| Incyte | Meals · 2025-09-08 | Monjuvi | $27 |
| Gilead Sciences | Meals · 2025-09-03 | Trodelvy | $32 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-02 | Lynparza | $27 |
| Merck Sharp & Dohme | Meals · 2025-08-28 | Keytruda | $22 |
| Novartis Pharmaceuticals | Meals · 2025-08-26 | Kisqali | $34 |
| SpringWorks Therapeutics | Meals · 2025-08-26 | Ogsiveo | $23 |
| Exelixis | Meals · 2025-08-25 | Cabometyx | $35 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-08-21 | Kisqali | $83 |
| Deciphera Pharmaceuticals | Meals · 2025-08-21 | Qinlock | $19 |
| Lilly USA | Meals · 2025-08-20 | Verzenio | $32 |
| Genmab U.S. | Meals · 2025-08-15 | Epkinly | $19 |
| Novartis Pharmaceuticals | Meals · 2025-08-13 | Scemblix | $3 |
| Novartis Pharmaceuticals | Meals · 2025-08-13 | Scemblix | $22 |
| Pfizer | Meals · 2025-08-12 | Elrexfio | $21 |
| Janssen Biotech | Meals · 2025-08-08 | Tecvayli | $33 |
| Incyte | Meals · 2025-08-06 | Jakafi | $26 |
| Eisai | Meals · 2025-08-06 | Lenvima | $32 |
| Daiichi Sankyo | Meals · 2025-08-05 | Enhertu | $29 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-05 | None | $16 |
| Stemline Therapeutics | Meals · 2025-07-30 | Orserdu | $31 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-29 | Opdivo | $26 |
| Pfizer | Meals · 2025-07-28 | Tivdak | $40 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-07-25 | Kisqali | $83 |
| Abbvie | Meals · 2025-07-24 | Epkinly | $25 |
| Novartis Pharmaceuticals | Meals · 2025-07-23 | Kisqali | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-16 | Imfinzi | $22 |
| Genentech USA | Meals · 2025-07-15 | Polivy | $30 |
| Celgene | Meals · 2025-07-14 | Reblozyl | $25 |
| Merck Sharp & Dohme | Meals · 2025-07-10 | Keytruda | $28 |
| Eisai | Meals · 2025-07-10 | Lenvima | $21 |
| Daiichi Sankyo | Meals · 2025-07-09 | Enhertu | $3 |
| Daiichi Sankyo | Meals · 2025-07-09 | Enhertu | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-08 | Opdivo | $22 |
| Janssen Biotech | Meals · 2025-07-04 | Tecvayli | $22 |
| Genentech USA | Meals · 2025-07-03 | Phesgo | $25 |
| Incyte | Meals · 2025-07-02 | Jakafi | $29 |
| Genmab U.S. | Meals · 2025-07-01 | Epkinly | $33 |
| Celgene | Meals · 2025-06-25 | Reblozyl | $28 |
| Pfizer | Meals · 2025-06-20 | Ibrance | $21 |
| Astellas Pharma US | Education · 2025-06-19 | None | $100 |
| Stemline Therapeutics | Meals · 2025-06-19 | Orserdu | $19 |
| Novartis Pharmaceuticals | Meals · 2025-06-18 | Kisqali | $33 |
| Pfizer | Meals · 2025-06-17 | Padcev | $14 |
| Pfizer | Meals · 2025-06-17 | Padcev | $3 |
| Puma Biotechnology | Meals · 2025-06-16 | Nerlynx | $22 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-06-12 | Kisqali | $83 |
| Incyte | Meals · 2025-06-09 | Monjuvi | $26 |
| Azurity Pharmaceuticals | Meals · 2025-06-09 | Danziten | $19 |
| Celgene | Meals · 2025-06-05 | Reblozyl | $31 |
| Gilead Sciences | Meals · 2025-06-04 | Trodelvy | $28 |
| Abbvie | Meals · 2025-06-03 | Elahere | $20 |
| Daiichi Sankyo | Meals · 2025-05-27 | Enhertu | $20 |
| Merck Sharp & Dohme | Meals · 2025-05-21 | Welireg | $34 |
| Lilly USA | Meals · 2025-05-15 | Verzenio | $32 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-05-15 | Kisqali | $83 |
| Daiichi Sankyo | Meals · 2025-05-14 | Enhertu | $28 |
| Gilead Sciences | Meals · 2025-05-12 | Trodelvy | $22 |
| Janssen Biotech | Meals · 2025-05-08 | Tecvayli | $27 |
| Novartis Pharmaceuticals | Meals · 2025-05-07 | Scemblix | $16 |
| Novartis Pharmaceuticals | Meals · 2025-05-07 | Scemblix | $2 |
| Daiichi Sankyo | Meals · 2025-05-06 | Enhertu | $27 |
| Syndax Pharmaceuticals | Meals · 2025-05-05 | None | $26 |
| Sun Pharmaceutical Industries | Meals · 2025-05-01 | Yonsa | $20 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-30 | None | $14 |
| BeOne Medicines USA | Meals · 2025-04-29 | Brukinsa | $25 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-04-24 | Kisqali | $83 |
| Gilead Sciences | Meals · 2025-04-24 | Trodelvy | $25 |
| Abbvie | Meals · 2025-04-23 | Venclexta | $18 |
| Merck Sharp & Dohme | Meals · 2025-04-23 | Keytruda | $26 |
| Genzyme | Meals · 2025-04-22 | None | $25 |
| Janssen Biotech | Meals · 2025-04-21 | Darzalex | $29 |
| Daiichi Sankyo | Meals · 2025-04-18 | Enhertu | $23 |
| Progenics Pharmaceuticals | Meals · 2025-04-17 | Pylarify | $23 |
| Pfizer | Meals · 2025-04-16 | Elrexfio | $11 |
| Janssen Biotech | Meals · 2025-04-10 | Carvykti | $25 |
| Janssen Biotech | Meals · 2025-04-07 | Rybrevant | $36 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-07 | Fruzaqla | $19 |
| Janssen Biotech | Meals · 2025-04-03 | Erleada | $29 |
| Aveo Pharmaceuticals | Meals · 2025-04-01 | Fotivda | $35 |
| Janssen Biotech | Meals · 2025-03-31 | Tecvayli | $27 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-03-26 | Kisqali | $83 |
| PharmaEssentia USA | Meals · 2025-03-26 | Besremi | $33 |
| Pfizer | Meals · 2025-03-21 | Bosulif | $25 |
| Pfizer | Meals · 2025-03-20 | Ibrance | $24 |
| Astellas Pharma US | Meals · 2025-03-19 | Vyloy | $23 |
| Array Biopharma | Meals · 2025-03-17 | Xalkori | $28 |
| Array Biopharma | Meals · 2025-03-17 | Xalkori | $1 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-13 | Opdivo | $27 |
| Pfizer | Meals · 2025-03-12 | Inlyta | $18 |
| Abbvie | Meals · 2025-03-11 | Epkinly | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-11 | Calquence | $25 |
| Abbvie | Meals · 2025-03-10 | Venclexta | $23 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-10 | None | $15 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-05 | Calquence | $14 |
| Gilead Sciences | Meals · 2025-03-05 | Trodelvy | $29 |
| Novartis Pharmaceuticals | Meals · 2025-03-03 | Scemblix | $23 |
| Novartis Pharmaceuticals | Meals · 2025-03-03 | Scemblix | $5 |
| Azurity Pharmaceuticals | Meals · 2025-03-03 | Danziten | $22 |
| Janssen Biotech | Meals · 2025-02-28 | Tecvayli | $22 |
| Teva Pharmaceuticals USA | Meals · 2025-02-28 | Austedo Xr | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-27 | Calquence | $25 |
| Abbvie | Meals · 2025-02-26 | Elahere | $23 |
| Novartis Pharmaceuticals | Meals · 2025-02-24 | Kisqali | $33 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-02-21 | Kisqali | $83 |
| Merck Sharp & Dohme | Meals · 2025-02-19 | Keytruda | $25 |
| Merck Sharp & Dohme | Meals · 2025-02-18 | Keytruda | $28 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-17 | Fruzaqla | $28 |
| Lilly USA | Meals · 2025-02-13 | Verzenio | $30 |
| GlaxoSmithKline | Meals · 2025-02-12 | Jemperli | $23 |
| Genentech USA | Meals · 2025-02-12 | Polivy | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-06 | Tagrisso | $24 |
| Karyopharm Therapeutics | Meals · 2025-02-04 | Xpovio | $29 |
| Teva Pharmaceuticals USA | Meals · 2025-02-04 | Austedo Xr | $16 |
| Novartis Pharmaceuticals | Meals · 2025-02-03 | Kisqali | $29 |
| Astellas Pharma US | Meals · 2025-01-30 | Xtandi | $25 |
| Array Biopharma | Meals · 2025-01-29 | Braftovi | $15 |
| Janssen Biotech | Meals · 2025-01-28 | Tecvayli | $21 |
| Daiichi Sankyo | Meals · 2025-01-28 | Enhertu | $28 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-01-23 | Kisqali | $83 |
| Abbvie | Meals · 2025-01-23 | Epkinly | $17 |
| Abbvie | Meals · 2025-01-23 | Epkinly | $2 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-22 | Vonvendi | $27 |
| Sobi | Meals · 2025-01-21 | Vonjo | $37 |
| Gilead Sciences | Meals · 2025-01-16 | Trodelvy | $27 |
| Genmab U.S. | Meals · 2025-01-14 | Epkinly | $28 |
| Teva Pharmaceuticals USA | Meals · 2025-01-14 | Austedo Xr | $17 |
| Agios Pharmaceuticals | Meals · 2025-01-09 | Pyrukynd | $21 |
| Regeneron Healthcare Solutions | Meals · 2025-01-08 | Libtayo | $37 |
| Incyte | Meals · 2025-01-07 | Jakafi | $25 |
| Daiichi Sankyo | Meals · 2025-01-06 | Enhertu | $24 |
| Teva Pharmaceuticals USA | Meals · 2025-01-03 | Austedo Xr | $17 |
| Novartis Pharmaceuticals | Meals · 2025-01-02 | Kisqali | $34 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $6,496
| Novartis Pharmaceuticals | Kisqali | $1,486 | 34 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $695 | 43 payments
|
| Pfizer | Tivdak | $324 | 14 payments
|
| Daiichi Sankyo | Enhertu | $291 | 15 payments
|
| Janssen Biotech | Carvykti | $287 | 11 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $276 | 10 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $265 | 11 payments
|
| Merck Sharp & Dohme | Keytruda | $255 | 9 payments
|
| Astellas Pharma US | Xtandi | $253 | 10 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $237 | 11 payments
|
| Abbvie | Venclexta | $167 | 9 payments
|
| Gilead Sciences | None | $150 | 6 payments
|
| Celgene | Reblozyl | $145 | 6 payments
|
| GlaxoSmithKline | Jemperli | $128 | 6 payments
|
| Incyte | Jakafi | $127 | 5 payments
|
| Exelixis | Cabometyx | $124 | 4 payments
|
| Stemline Therapeutics | Orserdu | $104 | 4 payments
|
| Lilly USA | Verzenio | $94 | 3 payments
|
| PharmaEssentia USA | Besremi | $93 | 3 payments
|
| Array Biopharma | Xalkori | $92 | 4 payments
|
| Bayer Healthcare Pharmaceuticals | Stivarga | $77 | 3 payments
|
| EMD Serono | None | $70 | 2 payments
|
| Genmab U.S. | Epkinly | $66 | 2 payments
|
| Genentech USA | Venclexta | $55 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $55 | 2 payments
|
| Blueprint Medicines | Ayvakit | $52 | 2 payments
|
| Karyopharm Therapeutics | Xpovio | $51 | 2 payments
|
| Eisai | Lenvima | $49 | 3 payments
|
| Coherus Biosciences | Udenyca | $43 | 2 payments
|
| Novocure | Optune | $42 | 2 payments
|
| ADC Therapeutics America | None | $41 | 2 payments
|
| Mirati Therapeutics | Krazati | $37 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $33 | 2 payments
|
| Sun Pharmaceutical Industries | Yonsa | $32 | 1 payment
|
| Genzyme | Enjaymo | $30 | 1 payment
|
| Puma Biotechnology | None | $29 | 1 payment
|
| Sobi | Doptelet | $27 | 1 payment
|
| Agios Pharmaceuticals | Pyrukynd | $24 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $20 | 1 payment
|
| Taiho Oncology | Lonsurf | $20 | 1 payment
|
| Emmaus Medical | Endari | $19 | 1 payment
|
| Azurity Pharmaceuticals | Vivimusta | $17 | 1 payment
|
| Tolmar | Eligard | $13 | 1 payment
|
2023: $7,081
| Bayer Healthcare Pharmaceuticals | Stivarga | $790 | 9 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $746 | 60 payments
|
| Novartis Pharmaceuticals | Tabrecta | $745 | 24 payments
|
| Exelixis | Cabometyx | $360 | 5 payments
|
| Janssen Biotech | Darzalex | $319 | 12 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $280 | 9 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $279 | 12 payments
|
| Pfizer | Ibrance | $279 | 16 payments
|
| Seagen | Adcetris | $266 | 8 payments
|
| Incyte | Jakafi | $240 | 8 payments
|
| GlaxoSmithKline | Jemperli | $236 | 6 payments
|
| Merck Sharp & Dohme | Keytruda | $189 | 8 payments
|
| Astellas Pharma US | Xtandi | $171 | 7 payments
|
| Daiichi Sankyo | Enhertu | $154 | 6 payments
|
| Amgen | Nplate | $154 | 9 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $152 | 6 payments
|
| Eisai | Lenvima | $140 | 9 payments
|
| Celgene | Opdualag | $130 | 6 payments
|
| Karyopharm Therapeutics | Xpovio | $112 | 4 payments
|
| Genzyme | Enjaymo | $104 | 4 payments
|
| Lilly USA | Verzenio | $100 | 4 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $100 | 4 payments
|
| Regeneron Healthcare Solutions | Libtayo | $95 | 3 payments
|
| Blueprint Medicines | Ayvakit | $79 | 3 payments
|
| ImmunoGen | Elahere | $75 | 3 payments
|
| Mirati Therapeutics | Krazati | $65 | 3 payments
|
| PharmaEssentia USA | Besremi | $60 | 2 payments
|
| AbbVie | Venclexta | $56 | 2 payments
|
| EMD Serono | Bavencio | $53 | 2 payments
|
| Agios Pharmaceuticals | Pyrukynd | $44 | 2 payments
|
| MorphoSys US | Monjuvi | $43 | 2 payments
|
| Progenics Pharmaceuticals | Pylarify | $31 | 1 payment
|
| Puma Biotechnology | None | $30 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $28 | 1 payment
|
| Taiho Oncology | Lonsurf | $28 | 1 payment
|
| Amneal Pharmaceuticals | Avastin | $28 | 1 payment
|
| Stemline Therapeutics | Orserdu | $27 | 1 payment
|
| Foundation Medicine | Foundationone Liquid Cdx | $27 | 1 payment
|
| Catalyst Pharmaceuticals | Firdapse | $26 | 1 payment
|
| Novocure | Optune | $26 | 1 payment
|
| Tolmar | Eligard | $24 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $23 | 1 payment
|
| Genentech USA | Alecensa | $23 | 1 payment
|
| Gilead Sciences | Trodelvy | $23 | 1 payment
|
| Rigel Pharmaceuticals | Rezlidhia | $20 | 1 payment
|
| Boston Scientific | Bodyguardian | $19 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $19 | 1 payment
|
| G1 Therapeutics | Cosela | $18 | 1 payment
|
| Secura Bio | Copiktra | $17 | 1 payment
|
| Kite Pharma | None | $16 | 1 payment
|
| Sobi | Doptelet | $14 | 1 payment
|
2022: $5,248
| Novartis Pharmaceuticals | Kisqali | $736 | 26 payments
|
| Teva Pharmaceuticals USA | Austedo | $659 | 41 payments
|
| Celgene | Pomalyst | $297 | 14 payments
|
| Incyte | Monjuvi | $292 | 11 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $241 | 12 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $229 | 6 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $220 | 7 payments
|
| Merck Sharp & Dohme | Keytruda | $201 | 10 payments
|
| Astellas Pharma US | Xtandi | $175 | 5 payments
|
| Eisai | Lenvima | $138 | 8 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $135 | 6 payments
|
| Seagen | Adcetris | $131 | 6 payments
|
| Amgen | Lumakras | $129 | 6 payments
|
| Janssen Biotech | Darzalex | $113 | 5 payments
|
| Exelixis | Cabometyx | $107 | 5 payments
|
| Lilly USA | Verzenio | $89 | 4 payments
|
| Pfizer | Bosulif | $85 | 4 payments
|
| Sobi | Doptelet | $82 | 4 payments
|
| TOLMAR Pharmaceuticals | Eligard | $80 | 4 payments
|
| Gilead Sciences | Trodelvy | $77 | 3 payments
|
| Daiichi Sankyo | Enhertu | $72 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $66 | 3 payments
|
| Myovant Sciences | Orgovyx | $63 | 3 payments
|
| MorphoSys US | Monjuvi | $60 | 3 payments
|
| Karyopharm Therapeutics | Xpovio | $58 | 2 payments
|
| Kite Pharma | None | $55 | 2 payments
|
| Blueprint Medicines | Ayvakit | $54 | 2 payments
|
| Genzyme | Enjaymo | $51 | 2 payments
|
| Genentech USA | Venclexta | $50 | 2 payments
|
| GE HealthCare | None | $45 | 2 payments
|
| Blue Earth Diagnostics | Axumin | $44 | 2 payments
|
| Taiho Oncology | Lonsurf | $44 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $39 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $36 | 2 payments
|
| Dendreon Pharmaceuticals | Provenge | $31 | 1 payment
|
| Emmaus Medical | Endari | $30 | 2 payments
|
| Myriad Genetic Laboratories | Myrisk | $27 | 1 payment
|
| GlaxoSmithKline | Zejula | $25 | 1 payment
|
| EUSA Pharma (US) | Sylvant | $25 | 1 payment
|
| Puma Biotechnology | Nerlynx | $24 | 1 payment
|
| Mylan Institutional | Ogivri | $24 | 1 payment
|
| PharmaEssentia USA | Besremi | $22 | 1 payment
|
| Global Blood Therapeutics | Oxbryta | $22 | 1 payment
|
| Epizyme | Tazverik | $22 | 1 payment
|
| EMD Serono | None | $21 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $20 | 1 payment
|
2021: $5,088
| Novartis Pharmaceuticals | Kisqali | $748 | 23 payments
|
| Teva Pharmaceuticals USA | Ajovy | $498 | 34 payments
|
| Seagen | Adcetris | $345 | 9 payments
|
| Pfizer | Ibrance | $298 | 15 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $249 | 11 payments
|
| Incyte | Monjuvi | $245 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $223 | 16 payments
|
| GlaxoSmithKline | Zejula | $213 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $200 | 7 payments
|
| Amgen | Lumakras | $160 | 6 payments
|
| Exelixis | Cabometyx | $138 | 5 payments
|
| Kite Pharma | None | $130 | 5 payments
|
| Lilly USA | Verzenio | $124 | 8 payments
|
| Genentech USA | Venclexta | $115 | 8 payments
|
| Merck Sharp & Dohme | Keytruda | $114 | 6 payments
|
| Taiho Oncology | Inqovi | $102 | 5 payments
|
| Dendreon Pharmaceuticals | Provenge | $97 | 3 payments
|
| Eisai | Lenvima | $90 | 4 payments
|
| Celgene | Reblozyl | $83 | 4 payments
|
| Genzyme | Elitek | $69 | 3 payments
|
| Karyopharm Therapeutics | Xpovio | $66 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $64 | 3 payments
|
| Dova Pharmaceuticals | Doptelet | $58 | 3 payments
|
| Astellas Pharma US | Xtandi | $58 | 3 payments
|
| Janssen Biotech | Erleada | $55 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $54 | 2 payments
|
| Blueprint Medicines | Gavreto | $49 | 2 payments
|
| EMD Serono | None | $46 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $46 | 2 payments
|
| Epizyme | Tazverik | $45 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $43 | 2 payments
|
| Myovant Sciences | Orgovyx | $42 | 2 payments
|
| Global Blood Therapeutics | Oxbryta | $39 | 2 payments
|
| Alexion Pharmaceuticals | None | $34 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Exkivity | $30 | 1 payment
|
| Myriad Genetic Laboratories | Myrisk | $23 | 1 payment
|
| TOLMAR Pharmaceuticals | Eligard | $22 | 1 payment
|
| Gilead Sciences | Trodelvy | $20 | 1 payment
|
| Emmaus Medical | Endari | $18 | 1 payment
|
| EUSA Pharma (US) | Sylvant | $17 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $16 | 1 payment
|
2020: $2,665
| Pfizer | Ibrance | $273 | 15 payments
|
| Novartis Pharmaceuticals | Kisqali | $179 | 8 payments
|
| Seagen | Adcetris | $170 | 4 payments
|
| Incyte | Jakafi | $161 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $142 | 7 payments
|
| Merck Sharp & Dohme | Keytruda | $137 | 7 payments
|
| GlaxoSmithKline | Zejula | $104 | 4 payments
|
| Genzyme | Sarclisa | $101 | 5 payments
|
| Janssen Biotech | Erleada | $99 | 4 payments
|
| Dova Pharmaceuticals | Doptelet | $85 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $83 | 4 payments
|
| Dendreon Pharmaceuticals | Provenge | $78 | 3 payments
|
| Exelixis | Cabometyx | $77 | 3 payments
|
| Lilly USA | Erbitux | $75 | 4 payments
|
| Eisai | Lenvima | $74 | 4 payments
|
| Genentech USA | Venclexta | $71 | 3 payments
|
| Astellas Pharma US | Xtandi | $69 | 3 payments
|
| Agios Pharmaceuticals | Tibsovo | $61 | 3 payments
|
| Amgen | Blincyto | $58 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nexavar | $54 | 3 payments
|
| Emmaus Medical | Endari | $49 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $46 | 2 payments
|
| TOLMAR Pharmaceuticals | Eligard | $43 | 2 payments
|
| Teva Pharmaceuticals USA | Bendeka | $41 | 2 payments
|
| Blueprint Medicines | Ayvakit | $39 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $36 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $36 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $32 | 2 payments
|
| Lexicon Pharmaceuticals | Xermelo | $24 | 1 payment
|
| Taiho Oncology | Lonsurf | $23 | 1 payment
|
| Global Blood Therapeutics | Oxbryta | $23 | 1 payment
|
| Puma Biotechnology | Nerlynx | $23 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $22 | 1 payment
|
| EMD Serono | Bavencio | $18 | 1 payment
|
| Innate Pharma | Lumoxiti | $16 | 1 payment
|
| Sirtex Medical | Sir-Spheres Microspheres | $15 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $15 | 1 payment
|
| Secura Bio | Farydak | $14 | 2 payments
|
2019: $2,626
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $313 | 12 payments
|
| Pfizer | Ibrance | $217 | 18 payments
|
| Novartis Pharmaceuticals | Mekinist | $213 | 11 payments
|
| Amgen | Neulasta | $151 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $131 | 11 payments
|
| Incyte | Jakafi | $129 | 7 payments
|
| Lilly USA | Cyramza | $129 | 7 payments
|
| Merck Sharp & Dohme | Keytruda | $103 | 6 payments
|
| Clovis Oncology | Rubraca | $92 | 4 payments
|
| Taiho Oncology | Lonsurf | $91 | 4 payments
|
| Genentech USA | Tecentriq | $90 | 5 payments
|
| Gilead Sciences | None | $79 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $76 | 5 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $74 | 4 payments
|
| Rigel Pharmaceuticals | Tavalisse | $58 | 2 payments
|
| Exelixis | Cabometyx | $58 | 2 payments
|
| Genzyme | Cablivi | $57 | 3 payments
|
| Celgene | Revlimid | $53 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $44 | 2 payments
|
| Secura Bio | Farydak | $36 | 3 payments
|
| TerSera Therapeutics | Zoladex | $34 | 2 payments
|
| Janssen Biotech | Darzalex | $30 | 1 payment
|
| Janssen Scientific Affairs | Imbruvica | $29 | 1 payment
|
| Teva Pharmaceuticals USA | Bendeka | $29 | 2 payments
|
| Puma Biotechnology | Nerlynx | $25 | 1 payment
|
| TOLMAR Pharmaceuticals | Eligard | $25 | 1 payment
|
| Verastem | Copiktra | $25 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $25 | 1 payment
|
| Novocure | Oncology | $24 | 1 payment
|
| Astellas Pharma US | Xospata | $24 | 1 payment
|
| Agios Pharmaceuticals | Tibsovo | $24 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $24 | 1 payment
|
| Jazz Pharmaceuticals | Vyxeos | $22 | 1 payment
|
| Lexicon Pharmaceuticals | Xermelo | $21 | 1 payment
|
| Eisai | Lenvima | $20 | 1 payment
|
| Tesaro | Zejula | $20 | 1 payment
|
| Seattle Genetics | Adcetris | $15 | 1 payment
|
| Emmaus Medical | Endari | $14 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · A Global, Phase 2 Study of Arx788 in Her2-Positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-Dxd · 2025 | Their institution | $369,317 |
| PFIZER INC. · A Study of Avelumab in Combination With Axitinib in Nonsmall Cell Lung Cancer Nsclc Or Urothelial Cancer Javelin Medley Vegf · 2019 | Their institution | $189,488 |
| Merck Sharp & Dohme LLC · A Phase 1 Open-Label Dose Escalation Trial of Bdb018 in Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors · 2025 | Their institution | $84,864 |
| Merck Sharp & Dohme LLC · A Phase 2, Open-Label, Single-Arm, Multicenter Study of Sot101 in Combination With Pembrolizumab To Evaluate the Efficacy and Safety in Patients With Selected Advanced,Refractory Solid Tumors · 2022 | Their institution | $74,164 |
| Janssen Research & Development, LLC · A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib As First-Line Treatment, Or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy As Second-Line Treatment, for Common Egfr-Mutated Loc · 2025 | Their institution | $71,579 |
| Merck Sharp & Dohme Corporation · A Phase 1,2 Study of Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers · 2021 | Their institution | $66,198 |
| Janssen Research & Development, LLC · Acebreast03 · 2024 | Their institution | $63,352 |
| Novocure Inc. · Ef-24 Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (Ttfields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-Small Cell Lung Cancer (Nsclc) Following Platinum Failure. · 2021 | Their institution | $53,914 |
| AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2024 | Their institution | $50,490 |
| PFIZER INC. · A Phase 1b2 Open Label Umbrella Study of Sasanlimab Combined With Anticancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Nonsmall Cell Lung Cancer Nsclc · 2020 | Their institution | $45,567 |
| Merck Sharp & Dohme Corporation · A Phase 1,2 Study of Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers · 2020 | Their institution | $32,400 |
| Janssen Research & Development, LLC · Ace-Breast-03 · 2024 | Their institution | $30,325 |
| Janssen Research & Development, LLC · 2024 | Their institution | $30,124 |
| AstraZeneca UK Limited · A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel As Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) · 2025 | Their institution | $27,104 |
| BioNTech SE · 2021 | Their institution | $24,614 |
| Novocure Inc. · Ef-24 Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (Ttfields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-Small Cell Lung Cancer (Nsclc) Following Platinum Failure. · 2023 | Their institution | $17,614 |
| Amgen Inc. · A Randomized, Double-Blind Study To Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between Abp 234 and Keytruda (Pembrolizumab) in Subjects With Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer · 2025 | Their institution | $17,350 |
| BioNTech SE · Pre-Commercial · 2023 | Their institution | $14,447 |
| BioNTech SE · 2024 | Their institution | $14,028 |
| Merck Sharp & Dohme LLC · A Phase 1,2 Study of Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers · 2022 | Their institution | $13,000 |
| BioNTech SE · 2022 | Their institution | $12,027 |
| Merck Sharp & Dohme LLC · A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2,3 Study To Evaluate the Safety and Efficacy of Eik1001 and Pembrolizumab Versus Placebo and Pembrolizumab As First-Line Therapy in Participants With Advanced Melanoma · 2025 | Their institution | $10,608 |
| PFIZER INC. · Phase 2 Study in Patients With Neoadjuvant Breast Cancer · 2020 | Their institution | $10,358 |
| PFIZER INC. · Treatment Resistance Following Anticancer Therapiestranslate · 2019 | Their institution | $10,275 |
| SANOFI US SERVICES INC. · Open-Label, Single-Arm Trial To Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Sar408701 Used in Combination With Ramucirumab in Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (Nsq Nsclc) Patients With Ceacam5-Positive Tumors, Previously Treated With Platinum-Based Chemotherapy and An Immune Checkpoint Inhibitor · 2021 | Their institution | $10,000 |
| ABBVIE INC. · A Study To Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared To IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (Nsclc) · 2022 | Their institution | $9,250 |
| Novocure Inc. · Ef-24 Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (Ttfields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-Small Cell Lung Cancer (Nsclc) Following Platinum Failure. · 2022 | Their institution | $7,238 |
| BioNTech SE · 2025 | Their institution | $6,850 |
| PFIZER INC. · A Phase 2 Non Randomized Open Label Single Arm Multi Center Study of Talazoparib for Neoadjuvant Treatment of Germline Brca12 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer · 2021 | Their institution | $6,066 |
| SANOFI US SERVICES INC. · Open-Label, Single-Arm Trial To Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Sar408701 Used in Combination With Ramucirumab in Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (Nsq Nsclc) Patients With Ceacam5-Positive Tumors, Previously Treated With Platinum-Based Chemotherapy and An Immune Checkpoint Inhibitor · 2023 | Their institution | $4,050 |
| Merck Sharp & Dohme LLC · A Phase 1,2 Study of Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers · 2024 | Their institution | $3,446 |
| Novocure Inc. · Ef-24 Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (Ttfields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-Small Cell Lung Cancer (Nsclc) Following Platinum Failure. · 2020 | Their institution | $3,400 |
| PFIZER INC. · A Phase 1b2 Open Label Umbrella Study of Sasanlimab Combined With Anticancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Nonsmall Cell Lung Cancer Nsclc · 2021 | Their institution | $3,114 |
| PFIZER INC. · Treatment Resistance Following Anticancer Therapiestranslate · 2021 | Their institution | $2,513 |
| ABBVIE INC. · A Study Evaluating Tolerability and Efficacy of Navitoclax Alone Or in Combination With Ruxolitinib in Participants With Myelofibrosis · 2025 | Their institution | $2,500 |
| PFIZER INC. · A Phase 1b2 Open Label Umbrella Study of Sasanlimab Combined With Anticancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Nonsmall Cell Lung Cancer Nsclc · 2023 | Their institution | $2,250 |
| Merck Sharp & Dohme LLC · A Phase 1,2 Study of Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers · 2023 | Their institution | $781 |
| SANOFI-AVENTIS U.S. LLC · Open-Label, Single-Arm Trial To Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Sar408701 Used in Combination With Ramucirumab in Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (Nsq Nsclc) Patients With Ceacam5-Positive Tumors, Previously Treated With Platinum-Based Chemotherapy and An Immune Checkpoint Inhibitor · 2021 | This clinician | $250 |
| Janssen Research & Development, LLC · Ace-Breast03 · 2024 | Their institution | $64 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Open-Label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-Dxd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment of Patients With Locally Advanced Or Metastatic Nsclc Without Actionable Genomic Alterations (D926nc00001; Avanzar) · 2024 | Their institution | $63 |
| Merck Sharp & Dohme LLC · Neoadjuvant Combination Biotherapy With Pembrolizumab Mk-3475 and High Dose Ifn- 2b in Patients With Locally,Regionally Advanced,Recurrent Melanoma# Safety, Efficacy and Biomarker Study · 2024 | Their institution | $25 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 87.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1821382250
- Licence
- CA A149539, NY 276339California A149539: Current · expires 2027-01-31
- Group
- Piedmont Providers LLC · The Oncology Institute CA, A Professional Corporation
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 1800 Tree Ln Ste 350, Snellville, GA, 30078
- NPI first listed
- 2011-06-02
- NPI last updated
- 2025-10-22
- NPI record certified
- 2025-10-22
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1513 S Grand Ave Ste 360, Los Angeles, CA, 90015